Novo Nordisk A/S Common Stock (NVO)
Stock · NYSE · Health Care
$38.82as of 10/16/2026
Price chart
Active signals
NVO Signal Track Record
How signals performed across all stocks →What NVO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | +2.2% | 56% | September 21, 2026 |
| Bollinger Band Breakout | 24 | +1.6% | 58% | June 23, 2026 |
| Bollinger Band Breakdown | 17 | -3.7% | 47% | September 11, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -1.2% | 46% | August 28, 2026 |
| Any 20-session window (baseline) | +1.2% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare b…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 66,700
- Website
- www.novonordisk.com/
Fundamentals
- 1-day range
- $38.89$39.68
- Market cap
- $203.55B
- P/E (trailing)
- 9.74
- P/E (forward)
- 11.44
- EPS (trailing)
- $26.18
- Dividend yield
- 1.00%
- Beta
- 1.96
- Avg. volume
- 12.82M
- Ex-dividend date
- August 17, 2026
- Dividend pay date
- August 25, 2026
Forecasts
12 analyst ratings
Novo Nordisk A/S Common Stock Competitors
Chosen by industry and closest market cap.
- NVONovo Nordisk A/S Common Stock$38.83▼ 0.99%Market cap $203.55BP/E 9.74$224.25$409.95
- ABTAbbott Laboratories Common Stock$104.89▲ 0.20%Market cap $186.81BP/E 33.41$81.97$132.03
- AZNAstraZeneca PLC Ordinary Shares$165.41▼ 0.76%Market cap $249.78BP/E 24.19$11,404$15,730
- PFEPfizer Inc. Common Stock$29.58▲ 0.48%Market cap $149.33BP/E 39.08$23.62$29.49
- BMYBristol-Myers Squibb Company Common Stock$59.75▼ 1.35%Market cap $131.04BP/E 13.53$42.52$68.64
- VRTXVertex Pharmaceuticals Incorporated Common Stock$499.74▼ 1.77%Market cap $122.68BP/E 29.32$403.16$560.25
- NVSNovartis AG Common Stock$150.62▲ 0.16%Market cap $294.26BP/E 21.21$97.05$132.68
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NVO Novo Nordisk A/S Common Stock | $203.55B | 9.74 | $38.83 | ▼ 0.99% | $224.25$409.95 |
| ABT Abbott Laboratories Common Stock | $186.81B | 33.41 | $104.89 | ▲ 0.20% | $81.97$132.03 |
| AZN AstraZeneca PLC Ordinary Shares | $249.78B | 24.19 | $165.41 | ▼ 0.76% | $11,404$15,730 |
| PFE Pfizer Inc. Common Stock | $149.33B | 39.08 | $29.58 | ▲ 0.48% | $23.62$29.49 |
| BMY Bristol-Myers Squibb Company Common Stock | $131.04B | 13.53 | $59.75 | ▼ 1.35% | $42.52$68.64 |
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $122.68B | 29.32 | $499.74 | ▼ 1.77% | $403.16$560.25 |
| NVS Novartis AG Common Stock | $294.26B | 21.21 | $150.62 | ▲ 0.16% | $97.05$132.68 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?Yahoo · 10/10/2026
- Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell RightsYahoo · 10/10/2026
- Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average GrowthYahoo · 10/9/2026
- Citi Cuts Novo Nordisk Price Target to DKK 296 on Limited Margin Growth OutlookYahoo · 10/9/2026
- Novo Nordisk (CPSE:NOVO B) Gets FDA Review Update As New EASD Data LandYahoo · 10/9/2026
- Novo Nordisk stock target cut at Citi on lack of margin growthYahoo · 10/9/2026
- UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.Yahoo · 10/9/2026
- Novo Nordisk’s CEO Was Asked Why His Stock Keeps Falling on Good News: ‘The Stock Market Is Always Right, but With a Bit of a Time Difference’Yahoo · 10/8/2026
- Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Databenzinga · 10/2/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 403.38M
- Total value held
- $14.15B
- Institutional holders
- 1272
- Unknown31.02M
- Unknown20.14M
- Unknown19.33M
- Unknown17.02M
- Unknown16.08M
- Unknown12.88M
- Unknown11.80M
- Unknown11.06M
- Unknown10.87M
- Unknown10.77M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Novo Nordisk Shares Highlighted by Buyback, Value, Obesity Pipeline
Novo Nordisk’s recent share buyback has led analysts to suggest the stock may be undervalued by up to 63%. A separate review highlights the company as a long‑term value play, with an average target price of $45.83. An ETF focused on peptide drugs now includes Novo Nordisk, reflecting renewed interest in the obesity treatment space where the company is a leader.
Novo Nordisk Shares Highlighted by Buyback, Value, Obesity Pipeline. Novo Nordisk’s recent share buyback has led analysts to suggest the stock may be undervalued by up to 63%. A separate review highlights the company as a long‑term value play, with an average target price of $45.83. An ETF focused on peptide drugs now includes Novo Nordisk, reflecting renewed interest in the obesity treatment space where the company is a leader.